Abstract
The innate immune system accounts for the fastest defense response to microbial invasion although, conversely, several pathogens can modulate the host response resulting in a modulation of their survival and propagation. In this regard, some bacterial toxins possess immuno-stimulating properties that have been exploited in terms of vaccine adjuvanticity and induction of specific cytotoxic T lymphocytes. Among these, Bordetella pertussis toxin (PTX) possesses the ability of modulating the immune responses in multiple ways, as demonstrated in vivo as well as in ex-vivo and in vitro experimental systems. In addition, PTX, as well its nontoxic B-oligomer PTX-B and the genetically inactivated PT-9K/129G molecule, have been recently shown to inhibit infection of primary cells, lymphoid organs and cervical tissue by the human immunodeficiency virus type 1 (HIV-1), the etiological agent of the acquired immunodeficiency syndrome. This article focuses on the regulation of the immune response and on the anti-viral properties of PTX and of its nontoxic related molecules as an example of exploitation of a natural bacterial product to combat viral infections.
Keywords: Pertussis toxin, HIV, tat, intracellular signaling, protein kinase C, adjuvant, microbicide.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:Pertussis Toxin (PTX) and its Non-Toxic Derivatives as Vaccine Adjuvant and Microbicide
Volume: 10 Issue: 5
Author(s): Massimo Alfano and Guido Poli
Affiliation:
Keywords: Pertussis toxin, HIV, tat, intracellular signaling, protein kinase C, adjuvant, microbicide.
Abstract: The innate immune system accounts for the fastest defense response to microbial invasion although, conversely, several pathogens can modulate the host response resulting in a modulation of their survival and propagation. In this regard, some bacterial toxins possess immuno-stimulating properties that have been exploited in terms of vaccine adjuvanticity and induction of specific cytotoxic T lymphocytes. Among these, Bordetella pertussis toxin (PTX) possesses the ability of modulating the immune responses in multiple ways, as demonstrated in vivo as well as in ex-vivo and in vitro experimental systems. In addition, PTX, as well its nontoxic B-oligomer PTX-B and the genetically inactivated PT-9K/129G molecule, have been recently shown to inhibit infection of primary cells, lymphoid organs and cervical tissue by the human immunodeficiency virus type 1 (HIV-1), the etiological agent of the acquired immunodeficiency syndrome. This article focuses on the regulation of the immune response and on the anti-viral properties of PTX and of its nontoxic related molecules as an example of exploitation of a natural bacterial product to combat viral infections.
Export Options
About this article
Cite this article as:
Alfano Massimo and Poli Guido, Pertussis Toxin (PTX) and its Non-Toxic Derivatives as Vaccine Adjuvant and Microbicide, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2011; 10 (5) . https://dx.doi.org/10.2174/1871523011109050358
DOI https://dx.doi.org/10.2174/1871523011109050358 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Physiology and Therapeutic Potential of the Thymic Peptide Thymulin
Current Pharmaceutical Design New Insights of CTLA-4 into Its Biological Function in Breast Cancer
Current Cancer Drug Targets Distinct Functions of Interleukin-10 Derived from Different Cellular Sources
Current Immunology Reviews (Discontinued) Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System
Current Pharmaceutical Design Small Molecules for Immunomodulation in Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry The Chemokine System as a Therapeutic Target in Autoimmune Thyroid Diseases: A Focus on the Interferon-γ Inducible Chemokines and their Receptor
Current Pharmaceutical Design Evaluation of the Effects of a New Drug on Brain Leukocyte Infiltration in an Experimental Model of Autoimmune Encephalomyelitis
Letters in Drug Design & Discovery Cellular and Biochemical Actions of Melatonin which Protect Against Free Radicals: Role in Neurodegenerative Disorders
Current Neuropharmacology Properties and Therapeutic Potential of Transient Receptor Potential Channels with Putative Roles in Adversity: Focus on TRPC5, TRPM2 and TRPA1
Current Drug Targets Role of Nitric Oxide and Reactive Oxygen Species in Arthritis
Current Pharmaceutical Design Complex and Differential Glial Responses in Alzheimer´s Disease and Ageing
Current Alzheimer Research CXCR3, CXCR5, CXCR6, and CXCR7 in Diabetes
Current Drug Targets Mesenchymal Stem Cell-Based Therapy for the Treatment of Type 1 Diabetes Mellitus
Current Stem Cell Research & Therapy Glycolipids as Immune Modulatory Tools
Mini-Reviews in Medicinal Chemistry Targeted Drug Delivery System for Platinum-based Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Nasal Drug Delivery System-Factors Affecting and Applications
Current Drug Therapy From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis
Current Neuropharmacology Acute Lymphoblastic Leukemia and Regulatory T cells: Biomarkers and Immunopathogenesis
Current Immunology Reviews (Discontinued) Use of Intravenous Immunoglobulin in the Treatment of Immune-Mediated Demyelinating Diseases of the Nervous System
Current Pharmaceutical Design Histone Modifier Differentially Regulates Gene Expression and Unravels Survival Role of MicroRNA-494 in Jurkat Leukemia
MicroRNA